UPGL00004 |
Catalog No.GC61365 |
UPGL00004 est un puissant inhibiteur allostérique de la glutaminase C (GAC) (IC50 = 29 nM ; Kd = 27 nM). UPGL00004 inhibe fortement la prolifération des lignées cellulaires de cancer du sein triple négatif très agressives.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1890169-95-5
Sample solution is provided at 25 µL, 10mM.
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC50=29 nM; Kd=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines[1].
UPGL00004 inhibits MDA-MB-231, HS578T and TSE cells with IC50s of 70, 129, and 262 nM, respectively[1].
The combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size in a triple-negative breast cancer patient-derived tumor graft model[1].
[1]. Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545.
Average Rating: 5
(Based on Reviews and 9 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *